Your browser is no longer supported. Please, upgrade your browser.
Settings
FGEN FibroGen, Inc. daily Stock Chart
FGEN [NASD]
FibroGen, Inc.
Index- P/E- EPS (ttm)-0.87 Insider Own4.60% Shs Outstand84.05M Perf Week-2.80%
Market Cap4.82B Forward P/E- EPS next Y-1.31 Insider Trans-13.95% Shs Float75.01M Perf Month-5.52%
Income-69.50M PEG- EPS next Q-0.33 Inst Own67.20% Short Float4.47% Perf Quarter-7.20%
Sales145.70M P/S33.08 EPS this Y1.00% Inst Trans5.46% Short Ratio7.40 Perf Half Y13.56%
Book/sh5.92 P/B9.69 EPS next Y-1.60% ROA-14.10% Target Price71.00 Perf Year8.72%
Cash/sh7.99 P/C7.17 EPS next 5Y- ROE-23.80% 52W Range40.74 - 68.55 Perf YTD20.99%
Dividend- P/FCF- EPS past 5Y-10.70% ROI-10.50% 52W High-15.97% Beta1.81
Dividend %- Quick Ratio8.00 Sales past 5Y13.80% Gross Margin- 52W Low41.38% ATR1.94
Employees423 Current Ratio8.00 Sales Q/Q45.20% Oper. Margin-84.90% RSI (14)39.61 Volatility3.66% 3.27%
OptionableYes Debt/Eq0.23 EPS Q/Q39.00% Profit Margin-85.60% Rel Volume0.55 Prev Close57.35
ShortableYes LT Debt/Eq0.23 EarningsAug 07 AMC Payout- Avg Volume453.39K Price57.60
Recom1.80 SMA20-3.45% SMA50-6.50% SMA2006.06% Volume77,739 Change0.44%
Aug-08-17Reiterated Stifel Buy $38 → $80
Aug-08-17Reiterated Leerink Partners Outperform $52 → $82
Jul-21-17Downgrade Goldman Buy → Neutral
Jul-11-17Initiated Jefferies Buy
Feb-11-16Upgrade Credit Suisse Neutral → Outperform $40
Jan-21-16Initiated Credit Suisse Neutral
Dec-04-15Initiated Citigroup Buy
Sep-23-15Initiated Lake Street Hold $25
Jul-29-15Initiated Citigroup Buy $37
Jul-20-15Upgrade Goldman Neutral → Buy
Dec-09-14Initiated Stifel Buy $39
Dec-09-14Initiated RBC Capital Mkts Outperform $38
Sep-19-18 03:02AM  Focus: AstraZeneca plots China robot offensive to counter price cuts Reuters
02:03AM  AstraZeneca plots China robot offensive to counter price cuts Reuters
01:08AM  AstraZeneca plots China robot offensive to counter price cuts Reuters
Sep-12-18 09:30AM  FibroGen Receives Fast Track Designation From the U.S. FDA for Pamrevlumab for the Treatment of Idiopathic Pulmonary Fibrosis GlobeNewswire
Sep-05-18 05:19AM  Boost for "made in China" medicine as Chi-Med wins key approval Reuters
Aug-15-18 07:55AM  New Research: Key Drivers of Growth for comScore, Fonar, FibroGen, Resolute Energy, National Commerce, and THL Credit Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire
Aug-07-18 07:20PM  FibroGen (FGEN) Reports Q2 Loss, Tops Revenue Estimates Zacks
06:13PM  FibroGen: 2Q Earnings Snapshot Associated Press
04:02PM  FibroGen Reports Second Quarter 2018 Financial Results GlobeNewswire
Aug-01-18 05:21PM  FibroGen to Report Second Quarter 2018 Financial Results on Tuesday, August 7, 2018 GlobeNewswire
Jul-10-18 07:45AM  Free Pre-Market Technical Pulse on FibroGen and Three More Biotech Stocks ACCESSWIRE
Jun-11-18 07:00AM  Blog Exposure - FibroGen Completed Enrollment in US Phase-3 Clinical Program for Roxadustat in CKD Associated Anemia ACCESSWIRE
Jun-07-18 07:00AM  FibroGen Announces Completion of Enrollment in U.S. Phase 3 Clinical Program for Roxadustat in Anemia Associated with Chronic Kidney Disease GlobeNewswire
Jun-04-18 02:05PM  FibroGen to Present at Two Upcoming Investor Conferences GlobeNewswire
Jun-03-18 09:30PM  FibroGen Presents Clinical Results of Pamrevlumab Treatment in Patients with Locally Advanced Unresectable Pancreatic Cancer at ASCO 2018 Annual Meeting GlobeNewswire
Jun-01-18 09:30AM  FibroGen Inc (NASDAQ:FGEN) Investors Are Paying Above The Intrinsic Value Simply Wall St.
May-21-18 04:00PM  FibroGen Presents Latest Data From PRAISE Phase 2b Study of Pamrevlumab in Idiopathic Pulmonary Fibrosis at American Thoracic Society 2018 GlobeNewswire
May-15-18 05:29PM  FibroGen Upgraded By Mizuho On Continued R&D Progress Benzinga
May-10-18 06:06PM  Edited Transcript of FGEN earnings conference call or presentation 9-May-18 9:00pm GMT Thomson Reuters StreetEvents -5.61%
May-09-18 05:31PM  FibroGen: 1Q Earnings Snapshot Associated Press
04:02PM  FibroGen Reports First Quarter 2018 Financial Results GlobeNewswire
May-02-18 07:00AM  FibroGen to Report First Quarter 2018 Financial Results on Wednesday, May 9, 2018 GlobeNewswire
Apr-27-18 07:45AM  Consolidated Research: 2018 Summary Expectations for MGM Growth Properties, Reinsurance Group of America, Cincinnati Bell, GAIN Capital, FibroGen, and First Hawaiian Fundamental Analysis, Key Performance Indications GlobeNewswire
Mar-05-18 07:40AM  Wired News FDA Granted Fast Track Designation to FibroGens Pamrevlumab for Locally Advanced Unresectable Pancreatic Cancer ACCESSWIRE
Mar-02-18 06:11PM  Edited Transcript of FGEN earnings conference call or presentation 27-Feb-18 10:00pm GMT Thomson Reuters StreetEvents
Mar-01-18 01:45PM  UPDATE - FibroGen Granted Fast Track Designation by U.S. FDA for Pamrevlumab Treatment of Patients with Locally Advanced Unresectable Pancreatic Cancer GlobeNewswire
07:55AM  Report: Developing Opportunities within Main Street Capital, United States Cellular, FibroGen, Cardiovascular, CDW, and ANSYS Future Expectations, Projections Moving into 2018 GlobeNewswire
07:00AM  Fibrogen Granted Fast Track Designation by U.S. FDA for Pamrevlumab Treatment of Patients with Locally Advanced Unresectable Pancreatic Cancer GlobeNewswire
Feb-28-18 05:04AM  FibroGen reports 4Q loss Associated Press -5.73%
Feb-27-18 04:11PM  FibroGen Reports Fourth Quarter and Full Year 2017 Financial Results GlobeNewswire
01:30PM  FibroGen, Inc. to Host Earnings Call ACCESSWIRE
12:53PM  FibroGen Q4 Earnings Outlook Benzinga
07:27AM  FibroGen Incs (NASDAQ:FGEN) Earnings Dropped -74.69%, Did Its Industry Show Weakness Too? Simply Wall St.
Feb-21-18 07:00AM  FibroGen to Report Fourth Quarter and Full Year 2017 Financial Results on Tuesday, February 27, 2018 GlobeNewswire
Feb-17-18 01:18PM  Why FibroGen Inc (NASDAQ:FGEN) Is A Financially Healthy Company Simply Wall St.
Jan-04-18 07:40AM  Report: Exploring Fundamental Drivers Behind K2M Group, Altra Industrial Motion, FibroGen, Cardiovascular, Bluerock Residential Growth REIT, and National Presto Industries New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire -5.27%
Jan-02-18 08:04AM  See what the IHS Markit Score report has to say about FibroGen Inc. Markit +6.96%
Jan-01-18 07:44AM  FibroGen, Inc. breached its 50 day moving average in a Bearish Manner : FGEN-US : January 1, 2018 Capital Cube
Dec-27-17 11:15AM  ETFs with exposure to FibroGen, Inc. : December 27, 2017 Capital Cube
Dec-15-17 01:21PM  ETFs with exposure to FibroGen, Inc. : December 15, 2017 Capital Cube
Dec-14-17 08:15PM  Edited Transcript of FGEN earnings conference call or presentation 8-Nov-17 10:00pm GMT Thomson Reuters StreetEvents
Dec-08-17 08:04AM  See what the IHS Markit Score report has to say about FibroGen Inc. Markit
Nov-27-17 08:04AM  See what the IHS Markit Score report has to say about FibroGen Inc. Markit
Nov-20-17 12:27PM  ETFs with exposure to FibroGen, Inc. : November 20, 2017 Capital Cube
Nov-15-17 08:07AM  See what the IHS Markit Score report has to say about FibroGen Inc. Markit
07:10AM  Corporate News Blog - Protalix BioTherapeutics Gets Positive Opinion for Orphan Designation of PRX-102 for Treatment of Fabry Disease in EU ACCESSWIRE
Nov-14-17 07:30AM  Featured Company News - FDA Approved Teligent's Betamethasone Dipropionate Ointment USP (Augmented), 0.05% ACCESSWIRE
Nov-13-17 09:34AM  FibroGen, Inc. :FGEN-US: Earnings Analysis: Q3, 2017 By the Numbers : November 13, 2017 Capital Cube
Nov-10-17 08:14AM  See what the IHS Markit Score report has to say about FibroGen Inc. Markit
07:58AM  FibroGen, Inc. breached its 50 day moving average in a Bearish Manner : FGEN-US : November 10, 2017 Capital Cube
Nov-08-17 06:07PM  ETFs with exposure to FibroGen, Inc. : November 8, 2017 Capital Cube
05:31PM  FibroGen reports 3Q loss Associated Press
04:02PM  FibroGen Reports Third Quarter 2017 Financial Results GlobeNewswire
02:10PM  FibroGen, Inc. to Host Earnings Call ACCESSWIRE
07:29AM  Is It Too Late To Buy FibroGen Inc (FGEN)? Simply Wall St.
Oct-30-17 08:00PM  FibroGen to Report Third Quarter Financial Results on Wednesday, November 8, 2017 GlobeNewswire
Oct-24-17 09:38AM  ETFs with exposure to FibroGen, Inc. : October 24, 2017 Capital Cube
Oct-18-17 09:29AM  Spectrum Shares Surge on Data for Lung Cancer Drug -- Biotech Movers TheStreet.com
07:00AM  FibroGen Announces Acceptance by China FDA of Roxadustat New Drug Application (NDA) for Treatment of Anemia Associated With Dialysis and Non-Dialysis Chronic Kidney Disease (CKD) GlobeNewswire
Oct-17-17 08:04AM  See what the IHS Markit Score report has to say about FibroGen Inc. Markit
Oct-13-17 10:47AM  ETFs with exposure to FibroGen, Inc. : October 13, 2017 Capital Cube
Oct-10-17 07:04PM  Cramer's lightning round: Let Nike walk these losses off CNBC Videos
Oct-02-17 11:14AM  3 Under-the-Radar Small Cap Gems Investopedia
10:50AM  ETFs with exposure to FibroGen, Inc. : October 2, 2017 Capital Cube
Sep-30-17 07:17AM  FibroGen Inc (FGEN): How Does It Impact Your Portfolio? Simply Wall St.
Sep-29-17 09:03AM  FibroGen, Inc. :FGEN-US: Earnings Analysis: Q2, 2017 By the Numbers : September 29, 2017 Capital Cube
Sep-28-17 08:04AM  See what the IHS Markit Score report has to say about FibroGen Inc. Markit
Sep-19-17 04:35PM  FibroGen Appoints Gerald Lema to Board of Directors GlobeNewswire
Sep-13-17 04:33PM  Why This Cancer Biotech Leads Pack After Hitting Record High Investor's Business Daily
07:00AM  Fibrogen Presents Latest Data From Phase 2b Study of Pamrevlumab in Idiopathic Pulmonary Fibrosis at European Respiratory Society (ERS) International Congress 2017 GlobeNewswire
Sep-06-17 07:14PM  Is There Now An Opportunity In FibroGen Inc (FGEN)? Simply Wall St.
Sep-05-17 04:05PM  FibroGen Announces Pamrevlumab Oral and Poster Presentations at European Respiratory Society International Congress 2017 GlobeNewswire
Aug-17-17 09:26AM  Biotech Movers: Red Hill Jumps After Securing Rights Sell GERD Treatment TheStreet.com
Aug-15-17 11:32PM  FibroGen, Inc. Announces Pricing of Follow-On Offering of Common Stock GlobeNewswire -6.24%
Aug-14-17 04:26PM  FibroGen, Inc. Announces Proposed Follow-On Offering of Common Stock GlobeNewswire +5.76%
Aug-12-17 08:04AM  See what the IHS Markit Score report has to say about FibroGen Inc. Markit
Aug-11-17 11:45PM  Edited Transcript of FGEN earnings conference call or presentation 7-Aug-17 9:00pm GMT Thomson Reuters StreetEvents
Aug-10-17 08:03AM  IHS Markit Score Update: Drop in demand for ETFs holding FibroGen Inc is a negative sign for its shares Markit -5.84%
Aug-09-17 08:46AM  Biotech Stock Roundup: Q2 Earnings from Regeneron, Kite & More, FibroGen Up on IPF Data Zacks -11.82%
08:43AM  Strength Seen in FibroGen (FGEN): Stock Soars 48.2% Zacks
Aug-08-17 04:20PM  Why Ralph Lauren, LendingClub, and FibroGen Jumped Today Motley Fool +48.20%
03:06PM  Why Did FibroGen (FGEN) Stock Hit All-Time High Today? Zacks
02:37PM  Why FibroGen Inc Skyrocketed Higher Today Motley Fool
11:07AM  Biotech FibroGen soars more than 50% on positive lung disease treatment study CNBC
10:55AM  Why Fibrogen Shares Are Exploding 24/7 Wall St.
10:54AM  FibroGen shares surge 49% on positive mid-stage trial for pulmonary fibrosis therapy MarketWatch
09:29AM  Biotech Movers: FibroGen Leaps on Results for Pulmonary Fibrosis Study TheStreet.com
Aug-07-17 11:00PM  FibroGen reports 2Q loss Associated Press
04:50PM  FibroGen Announces Positive Topline Results from Phase 2 Study of Pamrevlumab in Idiopathic Pulmonary Fibrosis GlobeNewswire
04:39PM  FibroGen Reports Second Quarter 2017 Financial Results GlobeNewswire
12:10PM  Investor Network: FibroGen, Inc. to Host Earnings Call ACCESSWIRE
Aug-03-17 08:51AM  Should You Buy FibroGen (FGEN) Ahead of Earnings? Zacks
Jul-31-17 07:00PM  FibroGen to Report Second Quarter Financial Results on Monday, August 7, 2017 GlobeNewswire
Jun-21-17 10:10PM  FibroGen Granted Orphan Drug Designation for Pamrevlumab in the Treatment of Pancreatic Cancer GlobeNewswire
Jun-13-17 07:00AM  About FibroGen, Inc.FibroGen to Present at the Goldman Sachs 38th Annual Global Healthcare Conference GlobeNewswire
Jun-05-17 07:00AM  European Patent Office Maintains FibroGen Patent Relating to Hypoxia-Inducible Factor (HIF) Prolyl Hydroxylase Inhibitor Technology GlobeNewswire
Jun-02-17 02:07PM  ETFs with exposure to FibroGen, Inc. : June 2, 2017 Capital Cube
08:41AM  FibroGen, Inc. breached its 50 day moving average in a Bullish Manner : FGEN-US : June 2, 2017 Capital Cube
May-24-17 09:01PM  Edited Transcript of FGEN earnings conference call or presentation 9-May-17 8:30pm GMT Thomson Reuters StreetEvents
May-22-17 01:39PM  ETFs with exposure to FibroGen, Inc. : May 22, 2017 Capital Cube
FibroGen, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes therapeutic agents to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development for the treatment of anemia in chronic kidney disease; Pamrevlumab, a human-monoclonal antibody that inhibits the activity of connective tissue growth factor, which is in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and Duchenne muscular dystrophy; and FG-5200, a corneal implant medical device for the treatment of corneal blindness resulting from partial thickness corneal damage. It has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. The company was incorporated in 1993 and is headquartered in San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Kurkijarvi KaleviDirectorSep 17Option Exercise2.904,00011,60027,700Sep 18 06:16 PM
Kurkijarvi KaleviDirectorSep 17Sale58.864,000235,45623,700Sep 18 06:16 PM
Cotroneo PatSVP, Finance and CFOSep 13Sale59.502,318137,921228,604Sep 14 05:19 PM
Cotroneo PatSVP, Finance and CFOSep 12Option Exercise2.9010,50030,450230,922Sep 14 05:19 PM
Routti JormaDirectorSep 10Option Exercise18.346,000110,040137,540Sep 12 04:54 PM
Routti JormaDirectorSep 10Sale57.316,000343,837131,540Sep 12 04:54 PM
Cotroneo PatSVP, Finance and CFOSep 10Sale57.351,01157,981220,422Sep 12 04:57 PM
Neff Thomas BChief Executive OfficerSep 07Option Exercise3.6010,32037,1522,753,314Sep 07 06:28 PM
Neff Thomas BChief Executive OfficerSep 07Sale56.7518,9001,072,6002,734,414Sep 07 06:28 PM
Neff Thomas BChief Executive OfficerSep 07Sale56.7491852,08498,466Sep 07 06:28 PM
Neff Thomas BChief Executive OfficerSep 06Option Exercise3.6010,32037,1522,761,894Sep 07 06:28 PM
Neff Thomas BChief Executive OfficerSep 06Sale58.2918,9001,101,5992,742,994Sep 07 06:28 PM
Neff Thomas BChief Executive OfficerSep 06Sale57.9791853,21699,384Sep 07 06:28 PM
Yu K PeonyChief Medical OfficerAug 31Option Exercise12.296,80083,585154,269Sep 05 06:37 PM
Tamura ToshinariDirectorAug 22Option Exercise19.0512,000228,60063,700Aug 24 07:25 PM
Tamura ToshinariDirectorAug 22Sale60.6512,000727,80051,700Aug 24 07:25 PM
Neff Thomas BChief Executive OfficerAug 21Option Exercise3.6010,32037,1522,779,133Aug 22 07:25 PM
Neff Thomas BChief Executive OfficerAug 21Sale60.5518,9001,144,3202,760,233Aug 22 07:25 PM
Neff Thomas BChief Executive OfficerAug 21Sale60.5991855,622100,302Aug 22 07:25 PM
Neff Thomas BChief Executive OfficerAug 20Option Exercise3.6010,32037,1522,787,713Aug 22 07:25 PM
Neff Thomas BChief Executive OfficerAug 20Sale59.9418,9001,132,9092,768,813Aug 22 07:25 PM
Neff Thomas BChief Executive OfficerAug 20Sale59.8291854,915101,220Aug 22 07:25 PM
Kurkijarvi KaleviDirectorAug 16Option Exercise2.904,00011,60027,700Aug 17 05:25 PM
Rosenkranz Roberto PedroDirectorAug 16Option Exercise9.781,0009,77533,700Aug 17 05:28 PM
Kurkijarvi KaleviDirectorAug 16Sale60.284,000241,12823,700Aug 17 05:25 PM
Rosenkranz Roberto PedroDirectorAug 16Sale60.281,00060,27932,700Aug 17 05:28 PM
Routti JormaDirectorAug 09Option Exercise18.006,000108,000137,540Aug 10 04:48 PM
Routti JormaDirectorAug 09Sale59.936,000359,579131,540Aug 10 04:48 PM
Neff Thomas BChief Executive OfficerAug 02Option Exercise3.6010,32037,1522,796,293Aug 03 04:58 PM
Neff Thomas BChief Executive OfficerAug 02Sale62.9018,9001,188,7232,777,393Aug 03 04:58 PM
Neff Thomas BChief Executive OfficerAug 02Sale62.8891857,724102,138Aug 03 04:58 PM
Neff Thomas BChief Executive OfficerAug 01Option Exercise3.6010,32037,1522,804,873Aug 03 04:58 PM
Neff Thomas BChief Executive OfficerAug 01Sale63.1118,9001,192,8472,785,973Aug 03 04:58 PM
Neff Thomas BChief Executive OfficerAug 01Sale63.0891857,907103,056Aug 03 04:58 PM
Kurkijarvi KaleviDirectorJul 19Option Exercise2.904,00011,60027,700Jul 20 06:07 PM
Neff Thomas BChief Executive OfficerJul 19Option Exercise3.6010,32037,1522,813,453Jul 20 06:08 PM
Rosenkranz Roberto PedroDirectorJul 19Option Exercise9.781,0009,77533,700Jul 20 06:10 PM
Kurkijarvi KaleviDirectorJul 19Sale64.354,000257,40023,700Jul 20 06:07 PM
Neff Thomas BChief Executive OfficerJul 19Sale64.3418,9001,216,0722,794,553Jul 20 06:08 PM
Neff Thomas BChief Executive OfficerJul 19Sale64.2791859,000103,974Jul 20 06:08 PM
Rosenkranz Roberto PedroDirectorJul 19Sale64.901,00064,90032,700Jul 20 06:10 PM
Neff Thomas BChief Executive OfficerJul 18Option Exercise3.6010,32037,1522,822,033Jul 20 06:08 PM
Neff Thomas BChief Executive OfficerJul 18Sale65.4818,9001,237,5992,803,133Jul 20 06:08 PM
Neff Thomas BChief Executive OfficerJul 18Sale65.4891860,111104,892Jul 20 06:08 PM
Routti JormaDirectorJul 09Option Exercise18.006,000108,000137,540Jul 11 06:59 PM
Routti JormaDirectorJul 09Sale67.716,000406,260131,540Jul 11 06:59 PM
Neff Thomas BChief Executive OfficerJul 06Option Exercise3.6010,32037,1522,830,613Jul 06 08:02 PM
Neff Thomas BChief Executive OfficerJul 06Sale65.8118,9001,243,8532,811,713Jul 06 08:02 PM
Neff Thomas BChief Executive OfficerJul 06Sale66.0291860,608105,810Jul 06 08:02 PM
Neff Thomas BChief Executive OfficerJul 05Option Exercise3.6010,32037,1522,839,193Jul 06 08:02 PM
Neff Thomas BChief Executive OfficerJul 05Sale64.1618,9001,212,5432,820,293Jul 06 08:02 PM
Neff Thomas BChief Executive OfficerJul 05Sale64.0191858,762106,728Jul 06 08:02 PM
Schoeneck James ADirectorJul 03Option Exercise2.907,63922,15311,339Jul 06 08:04 PM
Yu K PeonyChief Medical OfficerJul 03Option Exercise14.5815,645228,026163,114Jul 06 08:06 PM
Schoeneck James ADirectorJul 03Sale65.007,639496,5353,700Jul 06 08:04 PM
Yu K PeonyChief Medical OfficerJul 03Sale65.0015,6451,016,925147,469Jul 06 08:06 PM
Schoeneck James ADirectorJun 22Option Exercise2.904,36112,6478,061Jun 26 08:02 PM
Schoeneck James ADirectorJun 22Sale65.004,361283,4653,700Jun 26 08:02 PM
Neff Thomas BChief Executive OfficerJun 21Option Exercise3.6010,32037,1522,847,773Jun 22 05:46 PM
Rosenkranz Roberto PedroDirectorJun 21Option Exercise9.781,0009,77533,700Jun 22 05:48 PM
Neff Thomas BChief Executive OfficerJun 21Sale63.6518,9001,202,9192,828,873Jun 22 05:46 PM
Neff Thomas BChief Executive OfficerJun 21Sale63.6091858,385107,646Jun 22 05:46 PM
Rosenkranz Roberto PedroDirectorJun 21Sale63.651,00063,65032,700Jun 22 05:48 PM
Neff Thomas BChief Executive OfficerJun 20Option Exercise3.6010,32037,1522,856,353Jun 22 05:46 PM
Neff Thomas BChief Executive OfficerJun 20Sale63.5918,9001,201,9352,837,453Jun 22 05:46 PM
Neff Thomas BChief Executive OfficerJun 20Sale63.6091858,389108,564Jun 22 05:46 PM
Kurkijarvi KaleviDirectorJun 18Option Exercise2.904,00011,60027,700Jun 20 06:47 PM
Kurkijarvi KaleviDirectorJun 18Sale58.194,000232,76023,700Jun 20 06:47 PM
Cotroneo PatSVP, Finance and CFOJun 14Option Exercise25.407,750196,850232,454Jun 15 04:46 PM
Cotroneo PatSVP, Finance and CFOJun 14Sale60.007,750465,000224,704Jun 15 04:46 PM
Yu K PeonyChief Medical OfficerJun 14Sale59.203,422202,582147,469Jun 15 04:48 PM
Cotroneo PatSVP, Finance and CFOJun 13Sale57.702,319133,806224,704Jun 15 04:46 PM
Routti JormaDirectorJun 11Option Exercise9.786,00058,650137,540Jun 12 07:56 PM
Routti JormaDirectorJun 11Sale57.486,000344,880131,540Jun 12 07:56 PM
Cotroneo PatSVP, Finance and CFOJun 08Sale55.551,01156,161227,023Jun 08 07:18 PM
Neff Thomas BChief Executive OfficerJun 05Option Exercise3.6010,32037,1522,871,306Jun 05 07:42 PM
Neff Thomas BChief Executive OfficerJun 05Sale55.0218,9001,039,9592,852,406Jun 05 07:42 PM
Neff Thomas BChief Executive OfficerJun 05Sale54.9491850,435109,482Jun 05 07:42 PM
Cotroneo PatSVP, Finance and CFOJun 04Option Exercise19.396,013116,592236,324Jun 05 07:40 PM
Neff Thomas BChief Executive OfficerJun 04Option Exercise3.6010,32037,1522,879,886Jun 05 07:42 PM
Cotroneo PatSVP, Finance and CFOJun 04Sale55.166,013331,677230,311Jun 05 07:40 PM
Neff Thomas BChief Executive OfficerJun 04Sale54.7018,9001,033,8982,860,986Jun 05 07:42 PM
Neff Thomas BChief Executive OfficerJun 04Sale54.8091850,305110,400Jun 05 07:42 PM
Cotroneo PatSVP, Finance and CFOMay 21Option Exercise22.2014,987332,668246,291May 23 07:30 PM
Cotroneo PatSVP, Finance and CFOMay 21Sale55.0414,987824,884231,304May 23 07:30 PM
Kurkijarvi KaleviDirectorMay 17Option Exercise2.904,00011,60024,000May 18 04:04 PM
Neff Thomas BChief Executive OfficerMay 17Option Exercise3.6010,32037,1522,890,753May 18 04:06 PM
Rosenkranz Roberto PedroDirectorMay 17Option Exercise9.781,0009,77530,000May 18 04:07 PM
Kurkijarvi KaleviDirectorMay 17Sale51.834,000207,32020,000May 18 04:04 PM
Neff Thomas BChief Executive OfficerMay 17Sale51.6618,900976,3222,871,853May 18 04:06 PM
Neff Thomas BChief Executive OfficerMay 17Sale51.6291847,387111,318May 18 04:06 PM
Rosenkranz Roberto PedroDirectorMay 17Sale52.201,00052,20029,000May 18 04:07 PM
Neff Thomas BChief Executive OfficerMay 16Option Exercise3.6010,32037,1522,899,333May 18 04:06 PM
Neff Thomas BChief Executive OfficerMay 16Sale51.9918,900982,5452,880,433May 18 04:06 PM
Neff Thomas BChief Executive OfficerMay 16Sale52.0491847,773112,236May 18 04:06 PM
Routti JormaDirectorMay 09Option Exercise9.786,00058,650133,840May 11 04:34 PM
Routti JormaDirectorMay 09Sale47.106,000282,600127,840May 11 04:34 PM
Neff Thomas BChief Executive OfficerMay 03Option Exercise3.6010,32037,1522,907,913May 04 05:10 PM
Neff Thomas BChief Executive OfficerMay 03Sale46.7518,900883,5702,889,013May 04 05:10 PM
Neff Thomas BChief Executive OfficerMay 03Sale46.6391842,806113,154May 04 05:10 PM